Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction of High-dose Antipsychotic Therapy

Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction in Patients Undergoing High-dose Antipsychotic Therapy

Sponsors

Lead Sponsor: Juntendo University

Source Juntendo University
Brief Summary

To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.

Overall Status Unknown status
Start Date 2011-04-01
Primary Completion Date 2017-01-01
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Relationship between cognitive function and relapse with antipsychotic reduction Baseline
Enrollment 130
Condition
Intervention

Intervention Type: Drug

Intervention Name: risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine

Arm Group Label: reduction group

Eligibility

Criteria:

Inclusion Criteria: - inpatients with a diagnosis of schizophrenial, and - those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg CPZ eq./day. Exclusion Criteria: - mental retardation, - substance abuse or dependence, - a history of major head trauma, - serious medical or neurological disorders, or - depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months

Gender:

All

Minimum Age:

20 Years

Maximum Age:

70 Years

Healthy Volunteers:

No

Verification Date

2017-01-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Juntendo University

Investigator Full Name: Ryota Ataniya

Investigator Title: Clinician, graduate student

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: reduction group

Type: Experimental

Description: dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News